title: Current and emerging strategies in the management of Crohn's disease.
abstract: Diarrhoea is a common manifestation of Crohn's disease (CD). We advocate an evidence-based approach to treat the underlying disease and reduce symptoms. This article reviews disease grading systems, current concepts in medical therapy, and other treatments that may become available in the future. While some drug classes (e.g. salicylates, immunomodulators) have been studied for many decades, newer approaches including anti-TNF monoclonal antibodies (biologics), and gut selective agents are changing the paradigm we use to treat this debilitating condition.
authors: Gastroenterology Research of San Antonio (GERSA), University of Texas Health Science Center at San Antonio, TX, USA. drcwrandall@gmail.com
authors: Charles
authors: C
authors: Randall
authors: John
authors: J
authors: Vizuete
authors: Gregg
authors: G
authors: Wendorf
authors: Balaji
authors: B
authors: Ayyar
authors: Gregory
authors: G
authors: Constantine
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D003424:Crohn Disease / Q000175:diagnosis / Q000188:drug therapy*; D005765:Gastrointestinal Agents / Q000627:therapeutic use; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D012459:Salicylates / Q000627:therapeutic use; D013256:Steroids / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D007155:Immunologic Factors; D012459:Salicylates; D013256:Steroids